Somatic symptom disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Somatic symptom disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Duloxetine and Benztropine Mesylate for Patients with Severe Functional Somatic Disorder https://clinicaltrials.eu/trial/study-on-duloxetine-and-benztropine-mesylate-for-patients-with-severe-functional-somatic-disorder/ Wed, 29 Apr 2026 14:59:33 +0000 https://clinicaltrials.eu/trial/study-on-duloxetine-and-benztropine-mesylate-for-patients-with-severe-functional-somatic-disorder/ This clinical trial is focused on studying a condition known as Functional Somatic Disorder, which involves physical symptoms that cannot be fully explained by any underlying medical condition. The study aims to explore the effects of a patient education program and the use of medications on this disorder. The medications being tested include Cymbalta (duloxetine), which is commonly used to treat depression and anxiety, and Benztropine Mesylate, which is often used to treat symptoms of Parkinson’s disease. Additionally, a placebo will be used for comparison purposes.

The purpose of the study is to investigate the effectiveness of the patient education program and to examine biological factors related to functional disorders and diseases where inflammation plays a significant role. Participants will be randomly assigned to receive either the medication or a placebo, along with the education program. The study will last for a period of 13 weeks, during which participants will be monitored for changes in their health and well-being.

Throughout the study, participants will be asked to assess their health-related quality of life and overall improvement using various questionnaires. The study will also look at symptoms of anxiety and depression, as well as physical, mental, and social well-being. The results will help determine the impact of the treatment on the participants’ health and provide insights into the management of Functional Somatic Disorder.

]]>